Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback